Does pre-treatment with lamivudine prime for adefovir resistance of hepatitis B virus infection?

نویسندگان

  • Hüseyin Sirma
  • Anneke Funk
  • Wolfram Gerlich
  • Oliver Schildgen
چکیده

My recent leading article on silver-based products as antimicrobial agents was intended primarily to address microbiological issues such as bacterial susceptibility and the potential for the development of resistance to these products. Consequently, I did not consider the toxicological issues raised by Bayston et al. in their comment upon my article. Obviously, a heavy-metal cation such as silver has the potential to inhibit processes in mammalian cells and as noted by Bayston et al., various forms of silver-associated toxicity have been reported, although fortunately they are rare in clinical practice. Experience with antibiotics tells us that dosing with sub-MIC levels creates conditions favourable for the selection of resistant organisms. Applying these principles to the silver situation led me to conclude that products releasing high levels of silver were unlikely to generate conditions for the selection of silver-resistant microorganisms. However, I agree with Bayston et al. that the use of such products could pose a greater risk of toxicity than low silver release formulations and that the therapeutic index for silver-based products may be rather low. Concerning the issue of zones of inhibition raised by Bayston et al., it may well be true that free silver ions capable of diffusion are not released from nanoparticle systems. Unfortunately, the abstract, cited by Bayston et al., does not appear to support this claim. No zones of microbial inhibition were observed with the silver-impregnated catheters used by the authors, implying no diffusion of free silver ions from the catheter material. However, there appeared to be insufficient silver in this product even to affect the viability of bacteria (Staphylococcus epidermidis) bound to the catheter surface. Consequently, it is difficult for Bayston et al. to argue from these data that organisms attached to the surface of the catheter can be killed by silver in the absence of diffusion of the cation from the device.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus.

Fibrosing cholestatic hepatitis (FCH) is a severe clinical and histological variant of hepatitis B virus (HBV) infection seen most commonly in the HBV infected allograft after liver transplantation. Without treatment, FCH is fatal, rapidly and universally. Remission has been reported with lamivudine but is associated with evolving resistance to lamivudine. Adefovir dipivoxil has recently been r...

متن کامل

Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B.

The goals of antiviral therapy for hepatitis B patients on the liver transplantation (LT) waiting list are 2-fold: 1) to achieve clinical stabilization, thereby delaying/preventing the need for LT; and 2) to attain low hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels prior to transplant, thereby reducing the risk of recurrent HBV postLT. Lamivudine was the first nucleoside analog to b...

متن کامل

Use of ALLGIO probe assays for detection of HBV resistance to adefovir in patients with chronic hepatitis B, Kerman, Iran.

Hepatitis B virus (HBV) infection is contagious with transmissiobn vertically or horizontally by blood products and body secretions. Over 50% of Iranian carriers contracted the infection prenatally, making this the most likely route of transmission of HBV in Iran. To evaluate the resistance to adefovir (ADV) therapy in patients with chronic hepatitis B infection, a study was conducted on 70 pat...

متن کامل

Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis.

BACKGROUND Treatment options for chronic hepatitis B virus (HBV) infection have disparate risks and benefits. Interferon has clinically significant side effects, and lamivudine is associated with viral resistance. In contrast, adefovir is safe and has lower viral resistance but is more expensive. The most cost-effective approach is uncertain. OBJECTIVE To determine whether and under what circ...

متن کامل

Hepatitis B virus with primary resistance to adefovir.

The reverse-transcriptase inhibitor lamivudine (Zeffix, GlaxoSmithKline) is often used to treat chronic infection with hepatitis B virus (HBV) until resistance develops. Treatment may then be switched to the reverse-transcriptase inhibitor adefovir (Hepsera, Gilead), which has a lower frequency of resistance. Here, we describe three cases of primary adefovir resistance that were sensitive to te...

متن کامل

Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant

BACKGROUND Prolonged adefovir therapy exposes to the emergence of adefovir resistant hepatitis B virus mutants. Initial reports of the rtN236T mutation showed preserved sensitivity to lamivudine; however, complex mutations are emerging with reduced susceptibility to lamivudine. CASE PRESENTATION After 2 years of therapy, a cirrhotic patient developed the rtN236T and rtA181T adefovir resistant...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • The Journal of antimicrobial chemotherapy

دوره 60 2  شماره 

صفحات  -

تاریخ انتشار 2007